Search
Search Results
-
Glucagon-Like Peptide 1 Receptor Agonists for Obesity: Efficacy, Side Effects, and Risks
Purpose of ReviewThe glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) liraglutide and semaglutide, and the dual GLP-1/glucose-dependent...
-
Population Pharmacokinetic Modeling of Cotadutide: A Dual Agonist Peptide of Glucagon-Like Peptide and Glucagon Receptors Administered to Participants with Type II Diabetes Mellitus, Chronic Kidney Disease, Obesity and Non-Alcoholic Steatohepatitis
BackgroundCotadutide is a dual glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptor agonist peptide. The objective of this analysis was to...
-
Pharmacokinetics of Glepaglutide, A Long-Acting Glucagon-Like Peptide-2 Analogue: A Study in Healthy Subjects
Background and ObjectiveGlepaglutide is a novel, long-acting, glucagon-like peptide-2 analogue in a stable aqueous formulation for subcutaneous...
-
Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
This communication provides a contemporary classification of glucagon-like peptide 1 receptor agonists (GLP1RAs) based on indication, route, and...
-
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
Incretin hormones are peptides released in the intestine in response to the presence of nutrients in its lumen. The main incretins are glucagon-like...
-
Dairy Milk Protein–Derived Bioactive Peptides: Avengers Against Metabolic Syndrome
Purpose of ReviewMetabolic syndrome is continuously increasing among the world’s populations. Metabolic syndrome is a medical condition in which...
-
Glucagon-Like Peptide 1 Receptor Agonist Usage in Type 2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review
The scientific landscape of treatments for type 2 diabetes (T2D) has changed rapidly in the last decade with newer treatments becoming available....
-
Therapeutic peptides: current applications and future directions
Peptide drug development has made great progress in the last decade thanks to new production, modification, and analytic technologies. Peptides have...
-
A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) were first introduced for the treatment of type 2 diabetes (T2D) in 2005. Despite the...
-
Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis
BackgroundPrevious studies showed that type 2 short bowel syndrome (SBS) rats were accompanied by severe intestinal bacterial dysbiosis. Limited data...
-
A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a well-established class of glucose-lowering drugs. GLP-1 RAs can be classified according...
-
The Clinicopathological Significance of Tumor Cell Subty** in Appendiceal Neuroendocrine Tumors: A Series of 135 Tumors
Appendiceal neuroendocrine tumors (NETs) are common and often are identified as incidental lesions at the time of appendectomy. The guidelines for...
-
The Effect of Antrum Size on Weight Loss, Glucagon-Like Peptide-1 (GLP-1) Levels, and Glycemic Control Following Laparoscopic Sleeve Gastrectomy in Adolescents with Obesity and Type 2 Diabetes
PurposeThe aim of this study was to compare the effect of antral resection versus antral preservation sleeve gastrectomy on the post-operative GLP-1,...
-
Determinants of plasma levels of proglucagon and the metabolic impact of glucagon receptor signalling: a UK Biobank study
Aims/hypothesesGlucagon and glucagon-like peptide-1 (GLP-1) are derived from the same precursor; proglucagon, and dual agonists of their receptors...
-
The deletion of glucagon-like peptide-1 receptors expressing neurons in the dorsomedial hypothalamic nucleus disrupts the diurnal feeding pattern and induces hyperphagia and obesity
BackgroundFeeding rhythm disruption contributes to the development of obesity. The receptors of glucagon-like peptide-1 (GLP-1) are distributed in...
-
Emerging therapeutic options in the management of diabetes: recent trends, challenges and future directions
Diabetes is a serious health issue that causes a progressive dysregulation of carbohydrate metabolism due to insufficient insulin hormone, leading to...
-
Gut hormones and bone homeostasis: potential therapeutic implications
Bone resorption follows a circadian rhythm, with a marked reduction in circulating markers of resorption (such as carboxy-terminal telopeptide region...
-
Diabetes of the Exocrine Pancreas: Implications for Pharmacological Management
Post-pancreatitis diabetes mellitus, pancreatic cancer-related diabetes, and cystic fibrosis-related diabetes are often underappreciated. As a...
-
GLP-1 metabolite GLP-1(9–36) is a systemic inhibitor of mouse and human pancreatic islet glucagon secretion
Aims/hypothesisDiabetes mellitus is associated with impaired insulin secretion, often aggravated by oversecretion of glucagon. Therapeutic...
-
Efficiency of succinylated gelatin and amino acid infusions for kidney uptake reduction of radiolabeled αvβ6-integrin targeting peptides: considerations on clinical safety profiles
Purpose68 Ga-Trivehexin is an investigational PET radiopharmaceutical (NCT05799274) targeting αvβ6-integrin for PET imaging of carcinomas. 177 Lu-D0301...
